Remegen -H (9995.HK) traded down -0.08 % during a 24 hours period ending at 07:25 AM Central Europe on Tuesday 27th. One Remegen -H stock can currently be bought for about HKD 62.2 on popular exchanges. Current supply of Remegen -H stocks is 208.6 mn. Remegen -H has a current market capitalization of HKD 13.5 bn and approximately HKD 105 mn worth of Remegen -H was traded on exchanges in the last 24 hours. Since last month end, Remegen -H has traded -9.41 % down. Simple moving average of last 200 days is at HKD 84.04. The highest price of past 52 weeks was recorded at HKD 123.1 on 04/20/2026. 52 weeks low was at HKD 60 on 10/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Greater Bay Area Ai Computin (1396.HK) traded down -1.94 % and now trades at HKD 10.26. Greater Bay Area Ai Computin has a market capitalisation of HKD 16 bn.

  • Nanjing Gaoke (600064.SS) traded flat 0 % and now trades at CNY 7.87. Current market capitalisation for Nanjing Gaoke is CNY 13.7 bn. Current price/earnings ratio for Nanjing Gaoke is 7.98.

  • Harbin Pharmaceutical (600664.SS) traded flat 0 % and now trades at CNY 5.39. Harbin Pharmaceutical has a market capitalisation of CNY 13.7 bn. Harbin Pharmaceutical has a current price to earnings ratio of 27.89.

  • Shenzhen Hepalink Pharmace (002399.SZ) traded flat 0 % and now trades at CNY 9.13. Current market capitalisation for Shenzhen Hepalink Pharmace is CNY 13.7 bn. Shenzhen Hepalink Pharmace has a current price to earnings ratio of 67.53.

  • Shenzhen Microgate Technol (300319.SZ) traded flat 0 % and now trades at CNY 15.24. Shenzhen Microgate Technol has a market capitalisation of CNY 13.7 bn. Shenzhen Microgate Technol has a current price to earnings ratio of 37.83.

About Remegen -H

RemeGen Co., Ltd., a biotechnology company based in Yantai, China, specializes in developing therapeutic antibody drugs. These include antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and double antibodies. RemeGen provides solutions for autimmune diseases, tumor diseases, and ophthalmic diseases. You can find more information about their operations on their website, www.remegen.com , and they are listed on the Hong Kong Stock Exchange.